Geneos: DNA-based, personalized cancer vaccines

Inovio spin-out Geneos is taking its parent company’s plasmid delivery technology and IL-12 adjuvant into the realm of personalized neoantigen vaccines, with a little help from neoantigen discovery tech developed at the Wistar Institute.

Led by founder and CEO Niranjan Sardesai, formerly head of R&D and chief operating officer at Inovio Pharmaceuticals Inc. (NASDAQ:INO),  Geneos Therapeutics Inc. has raised $40 million and is backed by Inovio, Santé Ventures, Korea Investment Partners and Flerie Invest. ...